Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
(SWX:BSLN.SW),(Boerse Stuttgart – Freiverkehr:BSLN),(Boerse Berlin – Freiverkehr:BSLN),(Boerse Frankfurt – Freiverkehr:BSLN),(Boerse Muenchen – Freiverkehr:BSLN), Allschwil, Switzerland, February 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba(R) (isavuconazole), by […]